A structured approach for identifying disease analogs

Payers will often look to disease analogs when making pricing and coverage decisions. These disease analogs can inform the level of rebates, need for prior authorization/utilization management, and the drug’s cost sharing tier. Traditionally, however, disease analogs are selected on an ad hoc basis. In a recent JMCP paper titled “A structured approach for identifying…

Read More

Its Own Reward: NEMT Services Meet Challenge for Special Needs Patients

NEMT providers play a key role, providing lifelines by delivering the crucial connection between patients and the care they need. This responsibility becomes even more critical when serving individuals with special needs, such as those with physical disabilities, behavioral health conditions, developmental delays or age-related limitations. The post Its Own Reward: NEMT Services Meet Challenge…

Read More

As Shared Decision-Making Ails, AI May Save This Human Interaction

By MICHAEL MILLENSON Shared decision-making between doctors and patients may be “the pinnacle of patient-centered care,” but three new medical journal articles suggest it’s encountering more problems than peaks. Yet counterintuitively, it may be artificial intelligence that rescues this intimately human interaction. “Shared decision-making is at a crossroads,” declares a Perspective in the Journal of General…

Read More

Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot

Hansa Biopharma has encouraging early clinical results showing its drug imlifidase, used as a pretreatment, enabled Duchenne muscular dystrophy patients to receive the gene therapy Elevidys. Sarepta is searching for ways to mitigate excessive immune responses to Elevidys that can lead to serious and potentially fatal liver injury. The post Sarepta’s Future in Gene Therapy…

Read More